MX2013000369A - Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina. - Google Patents

Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.

Info

Publication number
MX2013000369A
MX2013000369A MX2013000369A MX2013000369A MX2013000369A MX 2013000369 A MX2013000369 A MX 2013000369A MX 2013000369 A MX2013000369 A MX 2013000369A MX 2013000369 A MX2013000369 A MX 2013000369A MX 2013000369 A MX2013000369 A MX 2013000369A
Authority
MX
Mexico
Prior art keywords
tobramycin
treatment
aerolisation
administration
lung infections
Prior art date
Application number
MX2013000369A
Other languages
English (en)
Other versions
MX336260B (es
Inventor
Thomas Norling
Original Assignee
Xellia Pharmaceuticals Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals Aps filed Critical Xellia Pharmaceuticals Aps
Publication of MX2013000369A publication Critical patent/MX2013000369A/es
Publication of MX336260B publication Critical patent/MX336260B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0091—Inhalators mechanically breath-triggered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención tiene que ver con una novedosa forma de administración y un nuevo régimen de administración útil en el tratamiento y prevención de infecciones bacterianas de pulmón en pacientes que lo requieren, en particular proveyendo una composición útil para la aerolización de una solución altamente concentrada de aminoglucósidos tales como la Tobramicina.
MX2013000369A 2010-07-12 2011-07-08 Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina. MX336260B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36333010P 2010-07-12 2010-07-12
NO20101576 2010-11-08
PCT/EP2011/003405 WO2012007130A1 (en) 2010-07-12 2011-07-08 Treatment of lung infections by administration of tobramycin by aerolisation

Publications (2)

Publication Number Publication Date
MX2013000369A true MX2013000369A (es) 2013-02-15
MX336260B MX336260B (es) 2016-01-13

Family

ID=45439015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000369A MX336260B (es) 2010-07-12 2011-07-08 Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.

Country Status (12)

Country Link
US (2) US8598131B2 (es)
EP (1) EP2593110B1 (es)
JP (1) JP6000946B2 (es)
KR (1) KR102012418B1 (es)
CN (2) CN103052392A (es)
AU (1) AU2011278693B2 (es)
BR (1) BR112013000921A2 (es)
CA (1) CA2803187C (es)
ES (1) ES2855159T3 (es)
MX (1) MX336260B (es)
RU (1) RU2597842C2 (es)
WO (1) WO2012007130A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DK2363114T3 (da) * 2002-10-29 2015-06-22 Insmed Inc Opretholdt afgivelse af anti-infektionsmidler
US7879351B2 (en) * 2002-10-29 2011-02-01 Transave, Inc. High delivery rates for lipid based drug formulations, and methods of treatment thereof
PT1962805T (pt) 2005-12-08 2016-10-05 Insmed Inc Composições de anti-infeciosos baseadas em lípidos para tratamento de infeções pulmonares
WO2007117550A2 (en) * 2006-04-06 2007-10-18 Transave, Inc. Methods for coacervation induced liposomal encapsulation and formulations thereof
US20100196455A1 (en) 2007-05-04 2010-08-05 Transave, Inc. Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
MX336260B (es) 2010-07-12 2016-01-13 Xellia Pharmaceuticals Aps Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
JP6402097B2 (ja) 2012-05-21 2018-10-10 インスメッド インコーポレイテッド 肺感染症を処置するためのシステム
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
WO2015175939A1 (en) 2014-05-15 2015-11-19 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
EP3214589A4 (en) * 2014-10-27 2017-11-22 Shenzhen Whalehouse Technology Company Limited Automatic warehouse control system and method
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
GB201815463D0 (en) * 2018-09-24 2018-11-07 Nerudia Ltd Aerosol delivery device
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment
CN111228243B (zh) * 2019-12-24 2022-02-18 珠海亿胜生物制药有限公司 一种雾化吸入用妥布霉素脂质体及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9401260A (nl) 1993-11-12 1995-06-01 Cornelis Johannes Maria Van Ri Membraan voor microfiltratie, ultrafiltratie, gasscheiding en katalyse, werkwijze ter vervaardiging van een dergelijk membraan, mal ter vervaardiging van een dergelijk membraan, alsmede diverse scheidingssystemen omvattende een dergelijk membraan.
US5508269A (en) 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5855564A (en) * 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
CZ20012147A3 (cs) * 1998-12-17 2003-01-15 Chiron Corporation Farmaceutický prostředek ve formě suchého práąku nebo rozpráąeného aerosolového prostředku pro léčení chronické bronchitidy
CA2399464C (en) * 2000-02-11 2008-10-07 Medic-Aid Limited Drug delivery apparatus
NL1016030C1 (nl) 2000-08-28 2002-03-01 Aquamarijn Holding B V Sproei inrichting met een nozzleplaat, een nozzleplaat, alsmede werkwijzen ter vervaardiging en voor toepassing van een dergelijke nozzleplaat.
EP2186508A3 (en) * 2001-05-18 2010-08-25 Novartis AG Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
EP1598059A1 (en) * 2001-05-18 2005-11-23 Chiron Corporation Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics
ES2222294T3 (es) 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
JP2003221335A (ja) * 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
PT1458360E (pt) * 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
EP1321159A1 (en) * 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP1340492A1 (en) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
ATE350024T1 (de) * 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
CA2900093C (en) * 2005-05-18 2018-11-13 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2006297289B2 (en) 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
RU2008136460A (ru) * 2006-02-10 2010-03-20 Пари Фарма ГмбХ (DE) Фармацевтический аэрозоль
ES2611583T3 (es) 2009-10-08 2017-05-09 Shl Group Ab Inhalador de gotitas de líquido dosificadas
MX336260B (es) 2010-07-12 2016-01-13 Xellia Pharmaceuticals Aps Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.

Also Published As

Publication number Publication date
AU2011278693A1 (en) 2013-01-24
WO2012007130A1 (en) 2012-01-19
ES2855159T8 (es) 2022-01-04
JP2013530248A (ja) 2013-07-25
ES2855159T3 (es) 2021-09-23
RU2013103534A (ru) 2014-08-20
CA2803187A1 (en) 2012-01-19
CN103052392A (zh) 2013-04-17
EP2593110B1 (en) 2021-01-06
MX336260B (es) 2016-01-13
US20140041654A1 (en) 2014-02-13
US8598131B2 (en) 2013-12-03
AU2011278693B2 (en) 2015-02-19
BR112013000921A2 (pt) 2016-05-17
CA2803187C (en) 2019-05-14
KR102012418B1 (ko) 2019-08-20
EP2593110A1 (en) 2013-05-22
KR20130130689A (ko) 2013-12-02
CN106074461A (zh) 2016-11-09
JP6000946B2 (ja) 2016-10-05
US9067032B2 (en) 2015-06-30
US20120010162A1 (en) 2012-01-12
RU2597842C2 (ru) 2016-09-20

Similar Documents

Publication Publication Date Title
MX336260B (es) Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
NZ602544A (en) Crystalline forms of a macrolide, and uses therefor
MX2012010671A (es) Compuestos antiinfecciosos.
NZ708928A (en) Mannose derivatives for treating bacterial infections
GEP20156370B (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EP4233545A3 (en) Synergistic bacterial compositions and methods of production and use thereof
MX2018001075A (es) Agentes terapeuticos y profilacticos antibacterianos.
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2015006681A (es) Formulaciones de vancomicina estabilizadas.
MX2009008617A (es) Uso de antagonistas de interleucina-23 para el tratamiento de infeccion.
MX352760B (es) Metodos para tratar infecciones intrapulmonares.
MX2015015506A (es) Peptidos antimicrobianos.
MX2011006803A (es) Agentes antibacterianos novedosos para el tratamiento de infecciones gram positivas.
MX2012000136A (es) Composiciones que comprenden finafloxacina y metodos para tratar infecciones oftalmicas, oticas, o nasales.
MX2017009094A (es) Derivado de polimixina y usos del mismo.
SG10201900541QA (en) Derivatives of xanthone compounds
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX2016007626A (es) Peptido antimicrobiano y usos del mismo.
MX2018011095A (es) Compuestos de carbapenem.
MX337145B (es) Composiciones farmaceuticas.
MX360559B (es) Péptidos antimicrobianos, composiciones que los comprende y usos.